Artisan Partners released its “Artisan Small Cap Fund” Q3 2025 investor letter, showing global equities rising with double-digit YTD gains. Major US indices hit record highs. The fund’s ARTSX returned 8.69%, APDSX 8.75%, and APHSX 8.73%. Insmed Incorporated (NASDAQ: INSM) stock increased by 190.08% over the last 52 weeks, closing at $193.22 on November 14, 2025.

Insmed Incorporated (NASDAQ: INSM) impressed Artisan Small Cap Fund in Q3 2025. The company develops therapeutic products for rare diseases. Insmed stock gained 190.08% in the last 52 weeks, closing at $193.22 on November 14, 2025. The firm’s lead product, ARIKAYCE®, treats lung infections with FDA approval for Brinsupri™.

Insmed Incorporated (NASDAQ: INSM) received praise from Artisan Small Cap Fund in Q3 2025. The firm focuses on pulmonary diseases and has a promising pipeline with multibillion-dollar potential. Insmed recently gained FDA approval for Brinsupri™, a treatment for non-cystic fibrosis bronchiectasis. The company’s stock soared after raising $650 million.

Insmed Incorporated (NASDAQ: INSM) is not among the 30 most popular stocks among hedge funds, with 82 hedge fund portfolios holding the stock at the end of Q2. While Insmed has investment potential, some AI stocks may offer greater upside with less risk. Explore our free report on the best short-term AI stock for more insights.

Read more at Yahoo Finance: Here’s What Lifted Insmed Incorporated (INSM) in Q3